Drs Mikhail Kosiborod and Neil Skolnik discuss this unique moment in the history of T2D management that offers treatments to address its broad cardiometabolic impact.
Three-quarters of stroke patients in a Swiss registry had at least 1 undiagnosed risk factor at the time of the event, most commonly hyperlipidemia or hypertension.
Slide Show: The AHA added sleep duration to its Life's Simple 7 cardiovascular health construct and updated sections on diet, lipids, blood glucose and smoking.
Statin-treated patients at high atherosclerotic risk experienced significantly slower progression of arterial stiffness vs those not taking statins in a cohort of more than 5000 patients.
Change in HbA1c as a guide for T2D treatment intensification is steadily yielding to presence of/risk for comorbidities as pluripotent agents win guideline favor, observes a VA clinical investigator.
The FDA ban yesterday on Juul vaping devices and nicotine e-liquid pods drew praise from the American Medical Association, American Thoracic Society, American Lung Association, among others.
Exercise began as foraging for survival for our hunter/gatherer forbears and is no less essential in our contemporary age of sitting and screen time. Take a quick trip through history.
How prevalent is NAFLD worldwide? What is the preferred treatment? And more questions to test your NAFLD knowledge.
A new study found patients with T1D and T2D had a greater risk for stenotic lesions, whereas risk for valvular regurgitation was lower in those with T2D.
ADA 2022: Reduction in risk of progression to type 2 diabetes of 60% was seen in STEP program clinical trial participants with overweight or obesity.